Evidence map›Paper›PMID 38356419›Full record

ArticleClinical and translational medicine2024

Blockade of V-domain immunoglobulin suppressor of T-cell activation reprograms tumour-associated macrophages and improves efficacy of PD-1 inhibitor in gastric cancer.

Yifan Cao, Kuan Yu, Zihao Zhang, Yun Gu, Yichao Gu, Wandi Li, Weijuan Zhang, Zhenbin Shen, Jiejie Xu, Jing Qin

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Clinical and translational medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed
4.3field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 18 citations in OpenAlex.

  1. Article
  2. Review
  3. Review
  4. Article
  5. Article
  6. Article
  7. DCC-2036 induces repolarization of TAMs to M1 type and enhances CD8Molecular therapy : the journal of the American Society of Gene Therapy · 2026
    Article
  8. Review
  9. Review
  10. Review
  11. Review
  12. Article
  13. Review
  14. Article
  15. Review
  16. Review
  17. Article
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 2 institutions in 1 country.

Yifan CaoDepartment of General Surgery, Zhongshan Hospital, Fudan University, Shanghai, China.
Kuan YuDepartment of General Surgery, Zhongshan Hospital, Fudan University, Shanghai, China.
Zihao ZhangDepartment of General Surgery, Zhongshan Hospital, Fudan University, Shanghai, China.
Yun GuDepartment of General Surgery, Zhongshan Hospital, Fudan University, Shanghai, China.
Yichao GuDepartment of General Surgery, Zhongshan Hospital, Fudan University, Shanghai, China.
Wandi LiDepartment of Immunology, School of Basic Medical Sciences, Fudan University, Shanghai, China.
Weijuan ZhangDepartment of Immunology, School of Basic Medical Sciences, Fudan University, Shanghai, China.
Zhenbin ShenDepartment of General Surgery, Zhongshan Hospital, Fudan University, Shanghai, China.
Jiejie XuDepartment of Biochemistry and Molecular Biology, School of Basic Medical Sciences, Fudan University, Shanghai, China.
Jing QinDepartment of General Surgery, Zhongshan Hospital, Fudan University, Shanghai, China.ORCID 0000-0001-8833-3165
Sun Yat-sen University · CNShanghai Medical College of Fudan University · CN

Funding

National Natural Science Foundation of China 81871926National Natural Science Foundation of China 82172694
6 · The paper itself

Abstract

BACKGROUND AND

aimsIn gastric cancer, the response rate of programmed cell death protein-1 (PD-1) inhibitor is far from satisfactory, indicating additional nonredundant pathways might hamper antitumour immunity. V-domain immunoglobulin suppressor of T-cell activation (VISTA) has been reported in several malignancies as a novel immune-checkpoint. Nevertheless, the role of VISTA in gastric cancer still remains obscure. Our purpose is to explore the clinical significance and potential mechanism of VISTA in affecting gastric cancer patients' survival and immunotherapeutic responsiveness.

methodsOur study recruited eight independent cohorts with a total of 1403 gastric cancer patients. Immunohistochemistry, multiplex immunofluorescence, flow cytometry or intracellular flow cytometry, quantitative polymerase chain reaction, western blotting, fluorescence-activated cell sorting, magnetic-activated cell sorting, smart-seq2, in vitro cell co-culture and ex vivo tumour inhibition assays were applied to investigate the clinical significance and potential mechanism of VISTA in gastric cancer.

resultsVISTA was predominantly expressed on tumour-associated macrophages (TAMs), and indicated poor clinical outcomes and inferior immunotherapeutic responsiveness. VISTA

conclusionsOur data revealed that VISTA was an immune-checkpoint associated with immunotherapeutic resistance. Blockade of VISTA reprogrammed TAMs, promoted T-cell-mediated antitumour immunity, and enhanced efficacy of PD-1 inhibitor, which might have implications in the treatment of gastric cancer.

Indexed as

Stomach NeoplasmsB7-H1 AntigenCD8-Positive T-LymphocytesHumansImmune Checkpoint InhibitorsImmunoglobulinsTumor-Associated MacrophagesB7-H1 AntigenImmune Checkpoint InhibitorsImmunoglobulinsgastric cancerimmunotherapyPD-1tumour-associated macrophagesVISTA

Identifiers

PMID38356419
PMCPMC10867598
OpenAlexW4391850232

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.